Lexicon Pharmaceuticals Aktie WKN: 936717 ISIN: US5288721047 Symbol: LXRX Typ: Aktie (Seite 14)

[butcherfriend]

Sieht auch Charttechnisch excellent aus-könnte ein Ausbruch bis 25 Dollar werden

[bernie55]

Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions

THE WOODLANDS, Texas, June 18, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that new clinical data for sotagliflozin will be presented at the upcoming 78th American Diabetes Association (ADA) Scientific Sessions in Orlando, FL, from June 22-26. The four accepted abstracts, including one oral presentation and two moderated poster discussions, reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need for potential new options for the management of type 1 diabetes.

Oral Presentation

Sunday, June 24, 3:45pm, Oral Presentation
Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) (#212-OR)

Moderated Poster Discussions

Saturday, June 23, 12:30pm, Moderated Poster Discussion, “Clinical Outcomes with Oral Therapies”
Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study) (#1122-P)

Sunday, June 24, 12:00pm, Moderated Poster Discussion, “Evolving Concepts in Clinical Management Strategies”
Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D (#5-LB)
Posters

Sunday, June 24, 12:00pm, General Poster Presentation
Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2) (#1179-P)

http://globenewswire.com/news-release/2018/06/18/1525684/0/e…

[bernie55]

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

GlobeNewswire•May 24, 2018
THE WOODLANDS, Texas, May 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference:

Jefferies 2018 Healthcare Conference on Thursday, June 7, 2018 at 3:00 p.m. EDT in New York, NY.

A live audio webcast for this conference will be available in the “Investors” section of the Lexicon website at www.lexpharma.com/. An archived version of the webcast will be available on the website for two weeks.

https://finance.yahoo.com/news/lexicon-pharmaceuticals-prese…

[bernie55]

Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update
GlobeNewswire•May 3, 2018

- XERMELO® (telotristat ethyl) Quarterly U.S. Net Sales of $5.4 Million

- Filings Submitted for Regulatory Approval of Sotagliflozin in Type 1 Diabetes

Consolidated Net Loss:
Net loss for the first quarter of 2018 was $42.1 million, or $0.40 per share, compared to a net loss of $34.9 million, or $0.33 per share, in the corresponding period in 2017. For the first quarter 2018 and 2017, net loss included non-cash, stock-based compensation expense of $3.1 million and $2.2 million, respectively.

Cash and Investments:
As of March 31, 2018, Lexicon had $262.3 million in cash and investments, as compared to $310.8 million as of December 31, 2017.

Anticipated Upcoming Milestones

2Q 2018 – Initiation of additional Phase 3 sotagliflozin study in type 2 diabetes by Sanofi

3Q 2018 – Phase 1b data for LX2761 in type 2 diabetes

June 2018 – Sotagliflozin data presentations at the American Diabetes Association 78th Scientific Sessions (ADA; June 22-26, 2018; Orlando, FL)

October 2018 – Sotagliflozin data presentations at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD; October 1-5, 2018; Berlin, Germany)

2H 2018 – Initiation of clinical studies for telotristat ethyl in neuroendocrine tumors and biliary tract cancers

2H 2018 – Phase 1a data for LX9211 in neuropathic pain

2018 – Manuscript publications for XERMELO and sotagliflozin

2018 – Launch of XERMELO by Ipsen in additional European countries

https://finance.yahoo.com/news/lexicon-pharmaceuticals-repor…

[bernie55]

Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes

GlobeNewswire•March 26, 2018

- New Drug Application Submitted to U.S. Food and Drug Administration

- Marketing Authorization Application Submitted to European Medicines Agency

THE WOODLANDS, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX), today announced that its collaborator, Sanofi, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.

“The NDA and MAA submissions for sotagliflozin represent important milestones for Lexicon and for people in the United States and Europe who are living with the challenges of type 1 diabetes,” said Pablo Lapuerta, M.D., executive vice president and chief medical officer. “These filings highlight our strong investment in internally discovered therapies and are a culmination of the largest Phase 3 program for an oral anti-diabetic agent ever conducted in type 1 diabetes, in the broadest range of patients, resulting in the most comprehensive efficacy and safety database. I am extremely proud of our team members who have worked tirelessly to achieve this step towards bringing this important potential therapy to patients with type 1 diabetes.”

“With approximately three-quarters of adult patients in the U.S. with type 1 diabetes not reaching their A1C goals, sotagliflozin would represent an important advance in managing these patients,” said Anne Peters, M.D., Professor of Medicine at the Keck School of Medicine of USC, Director of the USC Clinical Diabetes Programs and Chairman of the Sotagliflozin Type 1 Diabetes Steering Committee. “It potentially will be the first oral agent in the U.S. to be used in combination with insulin to improve glycemic control and patient outcomes.”


https://finance.yahoo.com/news/lexicon-pharmaceuticals-annou…

[bernie55]

3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Keith Speights, The Motley Fool
Motley Fool - January 21, 2018

Diabetes ranks as one of the top healthcare issues in the United States. Between 1990 and 2010, the number of Americans with diabetes tripled. By 2030, it's projected that nearly 55 million Americans will have diabetes -- a 54% increase from 2015.

With such a dire need, you'd think lots of companies would be developing products to help manage and treat diabetes. And you'd be right. The diabetes market has grown significantly and should continue to grow well into the future.


Lexicon Pharmaceuticals

Lexicon Pharmaceuticals stock could more than double if Wall Street analysts' price targets aren't too far off. If that happens, it would be a night-and-day difference between 2018 and 2017, when Lexicon stock plunged nearly 29%.
The company won FDA approval in February 2017 for its first commercial product, Xermelo, in treating carcinoid syndrome diarrhea. However, Lexicon's lead pipeline candidate, sotagliflozin, is an oral SGLT1/SGLT2 inhibitor for treating treatment of type 1 and type 2 diabetes.

Lexicon and its partner, Sanofi (NYSE: SNY), expect to submit for approval of sotagliflozin in the U.S. and Europe for treating type 1 diabetes in the first half of 2018. The two companies have already announced positive results from a couple of late-stage studies. Late-stage studies for type 2 diabetes are also now under way. The earliest of these studies should wrap up in 2019. 

If sotagliflozin wins approval, market research firm EvaluatePharma projects the drug could reach sales of nearly $1.2 billion by 2022. However, potential approval probably won't come until 2019.

Wall Street could be right on the price target for Lexicon, but the timing might be a little off.

https://finance.yahoo.com/news/3-fastest-growing-diabetes-st…

[bernie55]

LEXICON PHARMACEUTICALS INITIATES PATIENT DOSING IN A PHASE 1 STUDY OF LX9211

The Woodlands, Texas, September 27, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the company has initiated dosing in a Phase 1 study of LX9211, an orally-administered small molecule for the treatment of neuropathic pain. LX9211 is a selective inhibitor of AAK1 (adapter-associated kinase), which in preclinical studies demonstrated significant reduction in pain response in a series of pain models and was well-tolerated at and above efficacious doses in animals.

“The successful filing of the IND followed by initiation of the first-in-human clinical study for LX9211 are significant milestones for the company as these events validate our robust preclinical results and bring us closer to demonstrating clinical proof-of-concept for LX9211 in patients with neuropathic pain,” said Praveen Tyle, Ph.D., Lexicon’s executive vice president, research and development. “Based on animal data, LX9211 has the potential to significantly reduce pain response while offering a novel therapeutic approach to neuropathic pain through inhibition of AAK1. We look forward to producing important early data to guide our future development plans.”

The Phase 1 double-blind, placebo-controlled, single ascending dose study for LX9211 is designed to assess the safety, tolerability and pharmacokinetics of LX9211 across nine oral escalating dose levels (5 mg to 300 mg) in healthy volunteers.

http://www.lexpharma.com/media-center/news/653-lexicon-pharm…

[wohinistmeinGeld]

tja, nach 10 Jahren immer noch 50 % Minus, wird wohl auch die nächsten 10 Jahre so bleiben

[bernie55]

European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

PR NewswireSeptember 19, 2017

First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs

THE WOODLANDS, Texas, Sept. 19, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.(LXRX), announced today that the European Commission has approved XERMELO®(telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

This approval allows for the marketing of XERMELO by Lexicon's collaborator, Ipsen, in the above indication in all 28 member states of the European Union,Norway and Iceland.

Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs). XERMELO targets the overproduction of serotonin inside mNET cells, providing a new treatment option for patients suffering from carcinoid syndrome diarrhea.

https://finance.yahoo.com/news/european-commission-approves-…

[bernie55]

Antwort auf Beitrag Nr.: 55.703.889 von bernie55 am 09.09.17 12:01:39

Ein Experte hat wohl eine andere Meinung zu Sotaglifloxin....
....ein Grund für das aktuelle "Extrem-Down"....

Article. by Satish K. Garg, MD*
“The addition of sotagliflozin to existing insulin regimens improved glycemic control and led to reductions in the total, bolus and basal doses of insulin,” the researchers wrote. “A decrease in insulin dose may be a risk factor for diabetic ketoacidosis.”

In an accompanying editorial, David M. Nathan, MD, of the Diabetes Center at Massachusetts General Hospital and Harvard Medical School, wrote that the benefit of reducing HbA1c in people with type 1 diabetes may not outweigh the increased risk for diabetic ketoacidosis observed with sotagliflozin
.
In addition, he wrote, “further development of automated insulin delivery systems is likely to make adjunctive drug therapies for type 1 diabetes unnecessary.”

https://finance.yahoo.com/quote/LXRX/community?p=LXRX